Compare LZM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | RLMD |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.9M | 348.8M |
| IPO Year | 2023 | 2012 |
| Metric | LZM | RLMD |
|---|---|---|
| Price | $4.24 | $4.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.63 | ★ $10.75 |
| AVG Volume (30 Days) | 576.1K | ★ 1.6M |
| Earning Date | 07-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $182.86 | N/A |
| Revenue Next Year | $16.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $2.95 | $3.07 |
| 52 Week High | $6.40 | $8.00 |
| Indicator | LZM | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 59.22 |
| Support Level | $3.79 | $4.19 |
| Resistance Level | $4.17 | $4.53 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 68.75 | 66.78 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.